Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LA LEAST: 2-Year Adjuvant Endocrine Therapy for Low Risk Breast Cancer
NCT03917082Phase 2Active, not recruiting
- Sponsor
- BC Cancer
- Start
- Sep 2019
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tamoxifen in breast cancer, sponsored by BC Cancer. Started Sep 2019; status: active, not recruiting.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03917082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03917082.